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658 Am J PIn its decades-long history, the Division of Blood Disorders (DBD) at CDC has evolved from a
patient-focused, services-supporting entity at inception, to one of the world leaders in the practice
of public health to improve the lives of people at risk for or affected by nonmalignant blood
disorders. The DBD’s earliest public health activities consisted of working with care providers in a
network of hemophilia treatment centers to provide AIDS risk reduction services to people with
hemophilia. Because this infectious disease threat has been reduced over time as a result of the
development of safer treatment products, the DBD—under the auspices of congressional
appropriations guidance—has expanded its core activities to encompass blood disorders other
than hemophilia, including hemoglobinopathies such as thalassemia and sickle cell disease, and
Diamond Blackfan anemia. Simultaneously, in transitioning to a greater public health role, the
DBD has expanded its network of partners to new consumer and professional organizations, as well
as state and other federal health agencies. The DBD has also developed and maintains many
surveillance and registry activities beyond the Universal Data Collection system aimed at providing
a better understanding of the health status, health needs, and health-related quality of life of people
with nonmalignant blood disorders. The DBD has integrated applicable components of the
Essential Services of Public Health successfully to promote and advance the agenda of blood
disorders in public health.
(Am J PrevMed 2014;47(5):658–663) Published by Elsevier Inc. on behalf of American Journal of PreventiveMedicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionThe mission of CDC is to collaborate to createthe expertise, information, and tools that peopleand communities need to protect their health
through health promotion; prevention of disease, injury,
and disability; and preparedness for new health threats.1
CDC seeks to accomplish its mission by working with
partners throughout the nation and the world to monitor
health, detect and investigate health problems, conduct
research to enhance prevention, develop and disseminate
evidence-based public health policies, implement pre-
vention strategies, promote healthy behaviors, foster safe
and healthful environments, and provide leadership and
training.1 By applying the Essential Services of Publicof Blood Disorders (Parker, Tsai, Siddiqi, Richardson),
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open access article under the CC BY-NCHealth that describe the public health activities that all
communities should undertake and serve as the frame-
work for the National Public Health Performance Stand-
ards,2 the Division of Blood Disorders (DBD) within the
National Center on Birth Defects and Developmental
Disabilities at CDC monitors the epidemiology of non-
malignant blood disorders (hereafter referred to simply
as “blood disorders”) and supports efforts for the
prevention and management of these disorders.
The DBD initially developed and targeted activities and
interventions mainly for the community directly affected by
hemophilia. The primary need of this population was
intervening to prevent exposure to and transmission of
HIV.3,4 Institutionalized procedures to ensure the safe
donation and receipt of blood and blood products sub-
sequently have eliminated the transmission of HIV and
hepatitis B and C via these pathways.5–7 As people with
hemophilia live longer and more productive lives, they
experience many chronic conditions such as heart and renal
disease, joint deterioration, hypertension, and obesity at
rates similar to those among the general U.S. population.8–11
Effective management of these comorbidities, better
characterization of the risks for inhibitor development,
and identiﬁcation of prevention and treatment. on behalf of American Journal of Preventive Medicine. This is an
-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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this community. To meet these changing needs, the
division has shifted its focus from clinical concerns
related to HIV transmission to public health concerns
of the larger population with hemophilia. Additionally,
the DBD has expanded its portfolio of partners, pro-
grams, and projects to address the emerging needs of
populations with other blood disorders, such as venous
thromboembolism (VTE) and sickle cell disease (SCD),
which stand to beneﬁt from a public health practice
approach.
In April 2010, the DBD published the ﬁrst of two
journal supplements, titled “Blood Disorders in Public
Health: Making the Connection” in the American Journal
of Preventive Medicine, describing its move to streamline
and better align its programs and activities with CDC’s
agency mission and core functions.12 Based on the
information presented in the ﬁrst supplement, the
renewed vision of the DBD entailed becoming the global
leader in the practice of public health to improve the lives
of people at risk for or affected by blood disorders. The
DBD is working to achieve this vision by using and
promoting a comprehensive set of public health approaches
to reduce morbidity, mortality, and impaired health-related
quality of life among people with blood disorders. The
purpose of this article is to review the DBD’s progress in
advancing a public health agenda to improve the health
of people with blood disorders, and to propose ways to
integrate applicable components of the Essential Services
of Public Health to meet the emerging needs of this
population.
Inception of National Prevention Programs
for Blood Disorders
In 1975, a Congressional appropriation was awarded to the
Health Resources and Services Administration (HRSA) to
establish a program to support the provision of compre-
hensive care to people with hemophilia and their families
through an integrated regional network of centers—hemo-
philia treatment centers (HTCs)—for the diagnosis and
treatment of hemophilia and other bleeding disorders (Pub
L. 94-62).13 Subsequently, Congress awarded a separate
appropriation to CDC in 1983 to provide AIDS risk
reduction services for people with hemophilia and others
who relied on the use of blood products for treatment.
In 1996, CDC broadened its focus to a more compre-
hensive health approach that brought people (particu-
larly women) with bleeding and clotting disorders under
its mission purview. This comprehensive health
approach moved beyond health protection from infec-
tious agents to instituting programs to promote and
improve overall health.November 2014More recently, CDC’s approach to blood disorders was
broadened to encompass work in addressing many secon-
dary conditions including the health of people with disabling
or rare blood disorders, and women’s health issues, as well as
in acquiring high-capacity molecular diagnostic technology
and increasing the DBD’s intellectual expertise in genetics.
CDC received a funding appropriation for thalassemia in
2004 and another for Diamond Blackfan anemia in 2005,
and a year later, the appropriation for hemochromatosis was
moved from the National Center for Chronic Disease
Prevention and Health Promotion at CDC to the DBD as
part of an organizational realignment.
Early Work to Support Hemophilia
Treatment Centers
Early on, the DBD collaborated with the HTCs to ensure
replacement product safety and monitor for potential
outbreaks of bloodborne infections. In support of these
objectives, the DBD established the Universal Data
Collection (UDC) system, a public health surveillance
system employed throughout a network of 135 HTC
clinics across the U.S. and its territories.14 CDC’s
hemophilia program collaborates with the HRSA in
support of HTCs. The HTCs provide treatment and
multidisciplinary preventive health care to people with
bleeding and clotting disorders. Studies have shown that
this system of care has reduced mortality and morbidity
among patients with hemophilia.15,16
Historically, the hemophilia program has been the
largest blood disorder program continuously supported
by CDC from congressional appropriations. Based on
this program’s successful work in hemophilia surveil-
lance among people with bleeding disorders, congres-
sional appropriators expressed interest in CDC’s “efforts
to develop a surveillance system for deep vein thrombo-
sis”17 and encouraged CDC “to develop and implement a
hemoglobinopathy surveillance and registry program
with particular attention to SCD.”18 As a result, the
DBD has expanded activities to address other blood
disorders, including VTE and hemoglobinopathies.
Transition to a Public Health Approach
Within CDC, the DBD’s work has aligned with the
agency’s mission, transitioning from an initial clinical
treatment monitoring approach aimed primarily at
improving the care of patients with hemophilia to a
broader comprehensive set of public health approaches
such as pilot population–based surveillance of SCD and
VTE. During this transition, the DBD has prioritized its
activities by using criteria that encompass the magnitude
of the public health problem, the potential economic
Parker et al / Am J Prev Med 2014;47(5):658–663660savings and beneﬁts associated with decreasing mortality
and morbidity and improving quality of life, the dem-
onstrated effectiveness of interventions, and compliance
with healthcare reform and other legislation.
Subsequently, the division has instituted a four-step
process to achieve its goals, comprising (1) deﬁning and
monitoring the problem (public health surveillance); (2)
identifying risk and protective factors (epidemiologic and
health services research); (3) developing and testing pre-
vention strategies; and (4) ensuring widespread adoption of
effective prevention strategies. These changes were neces-
sary to meet the emerging needs of people with blood
disorders. In addition, the changes have allowed the division
to direct its resources more effectively to support these
surveillance, epidemiologic research, laboratory investiga-
tion, prevention research, and awareness activities among
those in the blood disorders community.
The transition to a public health approach has
afforded the DBD the opportunity to immediately
activate programs and projects aimed at promoting and
improving the health not only of people for whom a
blood disorder is an inheritable condition but also of the
hundreds of thousands for whom it might be a prevent-
able event. This approach, supported by the guidance
derived from the congressional appropriations process,
has allowed the DBD to expand its portfolio of surveil-
lance activities to address the lack of existing quality data
for conditions such as SCD and adverse events like VTE.
Equally important, this approach has allowed the divi-
sion to initiate prevention research activities needed to
identify vulnerabilities that conspire to produce dispa-
rately poor outcomes among certain populations.
More speciﬁcally, a broad public health approach has
extended the DBD’s reach from initially an approximate
20,000 people seen at HTCs to other patients with
bleeding disorders who are being treated outside the
HTCs and to the roughly 4 million people with one of the
targeted blood disorders. Additionally, it has afforded the
DBD the opportunity for pilot population–based (as
opposed to facility-based), individually targeted, registry-
like surveillance. Through this public health approach,
the DBD has sought to reposition itself from being an
agent for “better care” to an agent for “better health.”Efforts to Integrate Applicable Components
of the Essential Services of Public Health in
the Division of Blood Disorders
As enumerated in the following, the DBD has made
concerted efforts to integrate the ﬁve components of the
Essential Services of Public Health that are most appli-
cable to the work it performs.1. Monitor health status to identify community
health problems. Responding to the needs of individuals
with bleeding disorders and their families is an important
function of the DBD. However, attention has been given
to other conditions in addition to bleeding disorders and
providers beyond the HTCs. As a ﬁrst step in aligning the
functions of the DBDwith the Essential Services of Public
Health, the DBD assessed the epidemiology of blood
disorders—occurrence rates, characteristics of the con-
ditions, associated morbidities, and risk proﬁles of people
affected by them. In the area of hemoglobinopathies, the
DBD, in collaboration with the National Heart, Lung,
and Blood Institute (NHLBI), initiated the Registry and
Surveillance System in Hemoglobinopathies (RuSH), the
ﬁrst population-based public health surveillance system
for SCD and thalassemia.19,20 RuSH included seven states
whose combined populations, based on census tract data,
accounted for 42% of blacks or African Americans and
53% of Asian Americans residing in the U.S. This in-
novative surveillance program was designed to produce
needed data for participating states21 and federal health
agencies on the number of people affected by, mortality
statistics for, and healthcare costs associated with these
blood disorders. Data from this program also will be used
to strengthen health services and provide education and
outreach to patients and their families. In addition, the
DBD has initiated pilot projects to conduct population-
based surveillance of VTE and surveillance of hemophilia
among individuals who receive care outside the HTCs.
2. Diagnose and investigate health problems and
hazards in communities. To ensure that programs and
activities are evidence based and information driven, the
DBD has conducted and supported studies to deﬁne the
characteristics of affected populations and identify the risk
factors for and consequences of various blood disorders. For
example, the DBD conducted the national, cutting-edge
“Hemophilia Inhibitor Research Study,” which deﬁned the
patterns of antibody formation to factor VIII (FVIII) and
factor IX (FIX) and correlated this information with the
FVIII and FIX DNA sequences of individuals with hemo-
philia.22,23 The study’s accomplishments resulted in the
identiﬁcation of 151mutations that had not been previously
reported and led to the CDC Hemophilia A Mutation
Project (CHAMPS, an international database) in which
data on these mutations are recorded.24 In addition, the
DBD conducted analyses of nationally representative com-
plex sample surveys using administrative healthcare data
sets.25,26 As an example, the DBD acquired access to the
MarketScansMedicaidMulti-State, Commercial andMed-
icare Supplemental data to compare healthcare utilization
and expenditures among people in the U.S. with hemophilia
who were publicly insured to those with employer-
sponsored insurance.25www.ajpmonline.org
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issues. To raise awareness and help develop an agenda for
action related to blood disorders, the DBD participated in
the Healthy People 2020 process. This led to the addition of
a new topic area—blood disorders and blood safety—and
18 new, related objectives.27 Most of the published literature
related to blood disorders has been focused clinically, with
limited general applicability to a public health context. To
help address this issue, the DBD published two American
Journal of Preventive Medicine journal supplements on
blood disorders in public health. The ﬁrst supplement,
“Making the Connection” (April 2010), comprised peer-
reviewed articles in the areas of surveillance and burden of
disease.10 The second supplement, “Bridging the Gap”
(December 2011), included peer-reviewed articles on public
health practice, policy, and ﬁnance issues.28 The supple-
ments supported the development of a nationally recog-
nized public health framework for promoting the health of
and improving outcomes among people experiencing a
blood disorder by highlighting the potential of public health
strategies to address the complications they experience. In
addition to the special journal supplements, the DBD has
published its ﬁndings in many other peer-reviewed journals
and government reports. Through the RuSH project, the
DBD has published data collection ﬁeld reports and made
state-speciﬁc data on SCD accessible to the public.21,29,30
4. Mobilize community partnerships and action to
identify and solve health problems. In March 2010, in
partnership with the HRSA, NHLBI, American Society of
Hematology, and Hemophilia of Georgia, the DBD
hosted the ﬁrst National Conference on Blood Disorders
in Public Health. The conference served as a platform for
developing a nationally recognized public health frame-
work for promoting the health of and improving out-
comes among people with a blood disorder. Additionally,
the hosts highlighted the potential of public health
strategies to address complications experienced by people
with blood disorders. The results of a post-conference
evaluation suggested using Healthy People 2020 objec-
tives (rather than the Essential Services of Public Health)
as the framework for future National Conferences on
Blood Disorders in Public Health. Additional recom-
mendations included highlighting speciﬁc themes, such
as surveillance, workforce development, advocacy, out-
reach, awareness, and education techniques (e.g., webi-
nars, social media). Lastly, there was a strong call to
establish a blood disorders coalition with less segre-
gated sessions to speak for all blood disorders, pref-
erably under the umbrella of the American Society of
Hematology.
In 2010, the DBD established a moderated blood
disorders listserv that provided global access for its
partners to share and receive important blood disordersNovember 2014information. The listserv, with its global reach, provides a
repository for the immediate dissemination of informa-
tion on funding opportunity announcements, meetings,
group discussions, and other important happenings in
the ﬁeld.
Also in 2010, the DBD enhanced collaboration with
the WHO and other global partners to provide technical
assistance to countries with large populations affected by
hemoglobinopathies to develop national guidelines for
prevention and management and to promote regional
cooperation. In June 2011, the DBD supported a
Regional Meeting on Haemoglobinopathies and Genetic
Diseases with the WHO’s Regional Ofﬁce for the Eastern
Mediterranean. The meeting resulted in an agreement to
develop a regional strategy on the care of people with and
prevention of hemoglobinopathies and genetic disorders.
In addition, the DBD established the ﬁrst global health
initiative for hemoglobinopathies, successfully develop-
ing collaborations with Ghana, Kenya, and Nigeria to
improve population screening to identify people with
these blood disorders so that evidence-based, life-saving
prevention practices could be implemented. In Ghana,
the DBD partnered in the Genetic Education and
Counselling in Sickle Project to provide the follow-up
infrastructure for universal newborn screening. Informa-
tion derived from formative research conducted during
the period of 2010–2013 with mothers, healthcare work-
ers, and community leaders regarding knowledge and
attitudes about SCD, sickle cell trait, and newborn
screening for SCD will be used to develop the ﬁrst
genetic counselor training curriculum in Ghana.
In June 2011, the DBD, in conjunction with the Sickle
Cell Disease Association of America, hosted World SCD
Day in Atlanta, Georgia.31 The event galvanized global
support for promoting and improving the health of
people with SCD to aid in achieving UN Millennium
Development Goal 4 to reduce overall mortality among
children younger than age 5 years.
In March 2012, along with the partners from the 2010
conference, the DBD hosted a second National Confer-
ence on Blood Disorders in Public Health, incorporating
recommendations from the ﬁrst conference. The second
conference further advanced the public health context
described during the ﬁrst conference and proposed the
adoption and full integration of evidence based and
informed public health functions. Underlining its global
reach, the conference was held in conjunction with the
Conference of the Global SCD Network and the Second
Meeting of the Worldwide Initiative on Social Studies on
Hemoglobinopathies. Together, these conferences pro-
vided an impetus to move from examining process to
reporting effects in improving the health of populations
with blood disorders.
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personal and population-based health services and
promote and strengthen research for new insights into
and innovative solutions for health problems. In 2011,
the DBD evaluated and repurposed the UDC surveillance
system to monitor people with bleeding disorders,
including hemophilia A and B and von Willebrand
disease. The surveillance component was strengthened
to collect information on inhibitor development, chronic
conditions, and comorbidities in persons with bleeding
disorders. The anticipated impact of these efforts has
been enhanced data quality and availability that will
enable consumers, clinicians, public health professionals,
and policymakers to improve health outcomes among
people with blood disorders.
Additionally, the DBD has increased its laboratory
capacity by incorporating technology that has allowed
researchers to rapidly generate and analyze large
amounts of genetic information from many people, thus
facilitating large-scale genetic analysis that can be applied
to an entire target population. Molecular genetic studies
play an important role in public health by contributing to
the understanding of both the causes and effects of
diseases among different populations.32 An example of
the DBD’s use of this technology is resequencing of the β-
globin locus to redeﬁne its haplotypes more accurately, in
part to see if they can play a larger role in more precisely
deﬁning clinical phenotypes among children with SCD.33
Conclusions
As people with blood disorders are living longer and
more productive lives, many chronic conditions are
emerging as major challenges to further improvements
in their health outcomes. Public health practice provides
an effective means of addressing the emerging health
needs of people with blood disorders. The Essential
Services of Public Health provide a useful framework
for effective public health practice needed to promote
and improve the health of people with blood disorders.
Over the last several years, the DBD has successfully
integrated applicable components of this framework to
develop a comprehensive set of public health approaches
with its expanded network of partners to reduce morbid-
ity and mortality, and to improve the health-related
quality of life among populations at risk for or affected by
blood disorders.
The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the ofﬁcial position
of CDC.
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